What is Epigral Ltd (EPIGRAL) share price return in the past 10 years?

Data is not available for this company

What is the share price of Epigral Ltd (EPIGRAL)?

Company share prices are keep on changing according to the market conditions. The current trading price of Epigral Ltd (EPIGRAL) on 04-Jun-2026 16:59:59 at 16:59 is 1170.00.

What is the P/E ratio of Epigral?

The latest standalone P/E ratio of Epigral as of 04-Jun-2026 is 15.16.

What is the P/B ratio of Epigral Ltd (EPIGRAL)?

The latest standalone P/B ratio of Epigral Ltd (EPIGRAL) as of 04-Jun-2026 is 2.27.

What is the 52-week high and low of Epigral Ltd (EPIGRAL)?

The 52-week high of Epigral Ltd (EPIGRAL) is Rs. 2114.30 and the 52-week low is Rs. 806.20.

Epigral Ltd (EPIGRAL) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Epigral Ltd (EPIGRAL)
Brand: Epigral

Epigral Ltd (EPIGRAL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543332 NSE: EPIGRAL Chemicals | Small Cap | Epigral Share Price

Epigral Ltd (EPIGRAL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 543332 NSE: EPIGRAL Chemicals | Small Cap | Epigral Share Price

Key Metrics

Valuation Multiples

Market Cap

₹5,048 Cr.

Current Price

₹1,170

52-Week Low / High

₹806 / 2,114

TTM EPS

₹77.2

TTM Sales

₹2,527 Cr.

Book Value per Share

₹514.9

P/E Ratio

15.16

Lower than its 5-year historical median

Industry PE

50.2

Price to Book (P/B)

2.27

Lower than its 5-year historical median

Price to Sales (P/S)

2.00

Lower than its 5-year historical median

EV/EBITDA

9.63

Lower than its 5-year historical median

Dividend Yield

0.62%

Profitability Efficiency

Return on Equity (ROE)

16.15%

Outperforms industry median

Return on Capital Employed (ROCE)

15.69%

Outperforms industry median

Return on Assets (ROA)

10.01%

Operating Profit Margin

22.4%

Net Profit Margin

13.18%

Gross Profit Margin

19.1%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

-0.9%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-20.21%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

-6.64%

Asset Quality

Promoter Holding

68.83%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹2,178 Cr.

Equity

₹43.1 Cr.

Face Value

₹10

All Time Low / High

₹386.35 / 2408.35

Epigral stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Undervalued

Check Valuation charts

Price Trend

Semi Strong

Check Price chart

Q.1 Is Epigral Ltd a good quality company?

Epigral Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Epigral Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Epigral Ltd vs industry peers?

Epigral Ltd revenue CAGR is 24.99%, compared to the industry median CAGR of 7.53%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Epigral Ltd?

Promoters hold 68.83% of the Epigral Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Epigral Ltd over the last decade?

Over the last 3 year(s), the stock has delivered a CAGR of 10.74% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
ROCE % ⓘ	18.5%	37.9%	36.9%	15.9%	16.7%	29.4%	32.2%	17.5%	25.2%	15.7%	-
Value Creation Index ⓘ	0.3	1.7	1.6	0.1	0.2	1.1	1.3	0.3	0.9	0.1	-
Growth Parameters ⓘ
Sales ⓘ	392	598	710	611	829	1,551	2,188	1,929	2,550	2,527	2,527
Sales YoY Gr.	-	52.6%	18.9%	-14.1%	35.7%	87.2%	41.1%	-11.8%	32.2%	-0.9%	-
Adj EPS ⓘ	9.3	22	43.5	26.7	24	60.4	84.1	46.3	80.6	75.9	77.2
YoY Gr.	-	135.2%	97.8%	-38.5%	-10.1%	151.3%	39.4%	-45%	74.1%	-5.9%	-
BVPS (₹) ⓘ	51.1	73.1	68.4	89.7	113.9	174.7	257.3	301.8	441.2	514.9	514.9
Adj Net Profit ⓘ	66.1	155	179	111	99.8	251	350	192	348	327	333
Cash Flow from Ops. ⓘ	138	225	261	165	229	284	626	398	441	436	-
Debt/CF from Ops. ⓘ	0.9	0.3	1.5	3.2	2.4	3.5	1.4	2.4	1.3	1.3	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	23%	25%	4.9%	-0.9%
Adj EPS ⓘ	26.2%	25.9%	-3.4%	-5.9%
BVPSⓘ	29.3%	35.2%	26%	16.7%
Share Price	-	-	6.9%	-34.8%

Key Financial Parameters ⓘ

	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26	TTM
Return on Equity % ⓘ	20.1	35.4	35.4	20.6	15.8	35.6	39	16.6	22	15.9	15
Op. Profit Mgn % ⓘ	36.8	42.7	43.9	31.8	31.5	32.9	31.5	25	27.9	22.4	22.4
Net Profit Mgn % ⓘ	16.9	26	25.2	18.2	12.1	16.2	16	10	13.6	13	13.2
Debt to Equity ⓘ	0.3	0.1	0.8	0.9	0.8	1.4	0.8	0.8	0.3	0.3	0.2
Working Cap Days ⓘ	81	75	79	84	77	75	69	87	85	112	51
Cash Conv. Cycle ⓘ	35	28	25	34	26	40	41	40	36	56	10

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	392	598	710	611	829	1,551	2,188	1,929	2,550	2,527
Operating Expenses ⓘ +	247	342	399	416	567	1,041	1,499	1,448	1,839	1,960
Manufacturing Costs	40	48	38	52	70	163	234	227	274	325
Material Costs	173	238	255	275	385	761	1,115	1,061	1,353	1,430
Employee Cost	14	16	21	33	41	52	69	81	98	116
Other Costs ⓘ	21	40	83	57	71	65	82	79	114	89
Operating Profit ⓘ	144	255	312	194	261	509	689	481	711	567
Operating Profit Margin (%)	36.8%	42.7%	43.9%	31.8%	31.5%	32.9%	31.5%	24.9%	27.9%	22.4%
Other Income ⓘ +	1	4	14	9	7	8	9	7	15	15
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	14	9	30	17	34	48	67	73	53	72
Depreciation ⓘ	55	55	54	44	74	86	109	124	133	168
Profit Before Tax ⓘ	75	195	242	141	161	383	523	291	540	342
Tax ⓘ	9	40	59	29	60	131	169	95	183	9
Profit After Tax	67	155	183	112	101	253	353	196	357	333
PAT Margin (%)	17.0%	26.0%	25.7%	18.4%	12.2%	16.3%	16.2%	10.2%	14.0%	13.2%
Adjusted EPS (₹)	9.4	22.0	44.4	27.0	24.3	60.8	85.0	47.1	82.7	77.2
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	5.90%	10.60%	7.30%	6.50%

Valuation of Epigral - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	362	517	493	583	684	726	1,069	1,254	1,904	2,221
Share Capital ⓘ	71	71	252	252	252	42	42	42	43	43
Reserves ⓘ	291	447	241	331	432	684	1,028	1,213	1,860	2,178
Debt +	60	34	368	438	416	848	636	768	498	448
Long Term Debt	45	1	365	418	340	768	545	547	449	334
Short Term Debt	15	33	2	20	75	80	92	221	50	114
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	18	33	36	47	73	88	110	184	186	260
Others Liabilities ⓘ	82	79	147	204	276	461	617	588	564	576
Total Liabilities ⓘ	522	663	1,044	1,273	1,449	2,124	2,432	2,794	3,151	3,505
Fixed Assets
Net Fixed Assets ⓘ +	398	347	295	440	1,102	1,068	1,804	1,767	2,238	2,117
Gross Block	497	498	499	688	1,424	1,475	2,320	2,406	2,967	2,974
Accumulated Depreciation	99	150	204	248	321	407	516	639	729	857
CWIP ⓘ	3	79	468	691	126	589	158	483	64	451
Investments ⓘ	29	71	0	0	0	0	21	21	97	23
Inventories	28	30	41	48	54	154	212	263	388	349
Trade Receivables	44	77	77	76	119	256	166	179	232	417
Cash Equivalents	0	5	129	0	1	25	15	7	22	5
Others Assets ⓘ	20	54	34	16	47	31	56	76	110	144
Total Assets ⓘ	522	663	1,044	1,273	1,449	2,124	2,432	2,794	3,151	3,505

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	138	225	261	165	229	284	626	398	441	436
PBT ⓘ	75	195	242	141	161	383	523	291	540	342
Adjustment ⓘ	73	61	70	56	103	130	170	196	178	231
Changes in Working Capital ⓘ	10	7	8	-4	-6	-169	41	-38	-167	-64
Tax Paid ⓘ	-20	-38	-59	-28	-29	-60	-107	-51	-110	-73
Cash Flow From Investing Activity ⓘ +	-63	-167	-217	-363	-197	-455	-437	-401	-262	-355
Capex	-35	-122	-303	-369	-197	-456	-416	-398	-186	-385
Net Investments	-28	-112	82	2	-0	1	-1	-3	-75	30
Others ⓘ	0	68	4	4	0	0	-20	0	0	1
Cash Flow From Financing Activity ⓘ +	-76	-58	85	69	-32	195	-200	-8	-164	-94
Net Proceeds from Shares ⓘ	0	0	15	0	0	0	0	0	333	0
Net Proceeds from Borrowing ⓘ	0	0	350	110	-47	239	-64	17	-112	-86
Interest Paid ⓘ	-14	-9	-9	-37	-40	-48	-60	-72	-66	-49
Dividend Paid ⓘ	0	0	-3	0	0	0	-10	-10	-32	-15
Others ⓘ	-62	-49	-268	-4	54	4	-65	58	-288	55
Net Cash Flow ⓘ	-0	-0	129	-129	1	24	-11	-11	15	-14

Financial Ratio

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	20.26	35.37	45.75	34.23	23.85	42.16	39.37	16.85	22.59	16.15
ROCE (%)	18.45	37.92	36.88	15.9	16.74	29.4	32.2	17.5	25.22	15.69
Asset Turnover Ratio	0.84	1.04	0.85	0.55	0.63	0.9	1.02	0.77	0.91	0.8
PAT to CFO Conversion(x)	2.06	1.45	1.43	1.47	2.27	1.12	1.77	2.03	1.24	1.31
Working Capital Days
Receivable Days	37.10	36	38.80	44.20	41.60	42.70	33.30	31.40	27.90	44.30
Inventory Days	26.60	17.10	17.70	25.60	21.80	23.70	28.80	43.20	44.10	50.30
Payable Days	47.80	39.50	49.80	55.20	56.80	38.60	32.50	50.60	49.80	56.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Epigral Ltd FAQs

The current trading price of Epigral on 04-Jun-2026 16:59 is ₹1,170.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Epigral stood at ₹5,047.5 Cr

The latest P/E ratio of Epigral as of 03-Jun-2026 is 15.16.

The latest P/B ratio of Epigral as of 03-Jun-2026 is 2.27.

The 52-week high of Epigral is ₹2,114.3 and the 52-week low is ₹806.2.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Epigral is ₹2,527 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Epigral Ltd is a good quality company.

The key valuation ratios of Epigral Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Epigral Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

About Epigral Ltd

Meghmani Finechem Limited (MFL) is a Public Company limited by shares domiciled in India, incorporated under the provisions of Companies Act, 1956. The registered office of the company is located at GIDC Industrial Estate, Dahej, Tal. Vagara, Dist. Bharuch, Gujarat.

It is an ISO 9001 and ISO 14001-certified company founded in 2007 and recognised as one of the leading producers of chlor alkali and its Derivatives with backward and forward integration facilities. The Company meets the global essential chemicals demand with responsible care and with large-scale growth, while committing to quality and environment integrity.

MFL works out of an advanced automated production facility, which is equipped to address international standards in the manufacture of Caustic Soda, Caustic Potash, Chlorine, Hydrogen, Chloromethanes and Hydrogen Peroxide. The Company aims to service domestic as well as export markets, contributing towards the ‘Make in India’ initiative.

Business area of the company

The Company is primarily engaged in manufacturing and selling of Chlor Alkali & its Derivatives. The Company is also engaged in Trading of Agrochemical products.

Epigral Ltd (EPIGRAL)

Epigral Ltd (EPIGRAL)

Epigral stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Epigral - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Epigral Ltd FAQs

About Epigral Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Epigral Ltd (EPIGRAL)

Epigral Ltd (EPIGRAL)

Epigral stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Epigral - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Epigral Ltd FAQs

What is the share price of Epigral?

What is the market cap of Epigral?

What is the P/E ratio of Epigral?

What is the P/B ratio of Epigral?

What is the 52-week high and low of Epigral?

What is the TTM revenue of Epigral?

Is Epigral Ltd a good quality company?

Is Epigral Ltd undervalued or overvalued?

Is Epigral Ltd a good buy now?

About Epigral Ltd

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.